Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
ELI LILLY & Co director Juan R. Luciano received a small stock grant. He acquired 17.3030 shares of common stock as a grant or award at a reported price of $919.9000 per share. After this transaction, he directly holds a total of 16,834.7230 Eli Lilly common shares.
ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade. He acquired 10.78 shares of common stock at $919.90 per share through a grant classified as a “grant, award, or other acquisition.”
According to the footnote, he elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, his direct holdings total 75,269.556 Lilly common shares.
ELI LILLY & Co director Ralph Alvarez increased his equity-based compensation exposure through a deferred stock award. He acquired 13.498 shares of common stock equivalent as a grant or award at $919.90 per share, electing to defer cash compensation into stock units under the Lilly Directors' Deferral Plan.
After this award, his directly held common stock totaled 55,614.713 shares, with an additional 758 shares held indirectly by a trust. The deferred stock units will be settled in shares of common stock following his separation from service, and he disclaims beneficial ownership except to the extent of his pecuniary interest.
Lilly Endowment, Inc. reports beneficial ownership of 91,896,978 shares of Eli Lilly and Company common stock, representing 9.7% of the class as of March 31, 2026.
The filing states the 9.7% figure is based on 944,818,881 shares outstanding as of February 25, 2026, and the statement is signed April 20, 2026.
Eli Lilly & Co — Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned of Eli Lilly common stock, representing 0% of the class, following an internal realignment effective January 12, 2026. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.
Eli Lilly and Company is asking shareholders to vote on directors, executive pay, auditor ratification, and key governance changes at its 2026 virtual annual meeting. Management seeks approval to declassify the board, remove supermajority voting provisions, and opposes shareholder proposals on an independent chair and expanded lobbying disclosure.
The proxy highlights 2025 revenue of $65.2 billion, reported EPS of $22.95 and non-GAAP EPS of $24.21, along with a 40% 2025 total shareholder return that exceeded the S&P 500 and a peer group over one-, three-, and five-year periods. Incentive plans paid above target, with a 218% annual bonus payout and 200% payouts on three-year shareholder value and relative value awards, reflecting strong stock performance.
ELI LILLY & Co director Gabrielle Sulzberger reported a small stock-based compensation grant. She acquired 5.013 shares of common stock on March 16, 2026 at a price of $989.12 per share through a grant or award rather than an open-market purchase.
According to the disclosure, she elected to defer these shares as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after she separates from service. Following this grant, she directly holds a total of 2,976.209 shares of Eli Lilly common stock.
Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees. On 2026-03-16, he acquired 16.092 shares of common stock at $989.12 per share as a grant or award. Following this transaction, he directly holds 16,817.420 shares of Eli Lilly common stock.
According to the company’s directors’ deferral plan, these shares have been deferred as stock units in lieu of cash compensation and will be settled in actual shares of common stock after Luciano separates from service as a director.
ELI LILLY & Co director J. Erik Fyrwald reported a small stock-based compensation grant. He acquired 10.026 shares of common stock valued at $989.12 per share, increasing his direct holdings to 75,258.776 shares.
The filing notes he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in Eli Lilly common stock after he separates from board service. This is a routine director compensation transaction rather than an open-market purchase or sale.
Eli Lilly & Co director Ralph Alvarez reported an automatic stock-based compensation grant. On March 16, 2026, he acquired 12.553 shares of common stock at $989.12 per share as a grant or award, increasing his directly held position to 55,601.215 shares.
According to the company’s directors’ deferral plan, Alvarez elected to defer this award as stock units instead of cash compensation, to be settled in common shares after he leaves the board. The filing also shows an indirect holding of 758 shares held by a trust, for which he disclaims beneficial ownership beyond his economic interest.